273 related articles for article (PubMed ID: 27628127)
1. Long-term outcomes of high-dose-rate brachytherapy for intermediate- and high-risk prostate cancer with a median follow-up of 10 years.
Yaxley JW; Lah K; Yaxley JP; Gardiner RA; Samaratunga H; MacKean J
BJU Int; 2017 Jul; 120(1):56-60. PubMed ID: 27628127
[TBL] [Abstract][Full Text] [Related]
2. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
3. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
[TBL] [Abstract][Full Text] [Related]
4. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
5. Long-term oncological outcomes and toxicity in 597 men aged ≤60 years at time of low-dose-rate brachytherapy for localised prostate cancer.
Langley SEM; Soares R; Uribe J; Uribe-Lewis S; Money-Kyrle J; Perna C; Khaksar S; Laing R
BJU Int; 2018 Jan; 121(1):38-45. PubMed ID: 28670842
[TBL] [Abstract][Full Text] [Related]
6. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
Vicini FA; Kestin LL; Martinez AA
Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
Makino T; Mizokami A; Namiki M
Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
[TBL] [Abstract][Full Text] [Related]
8. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.
Jabbari S; Weinberg VK; Shinohara K; Speight JL; Gottschalk AR; Hsu IC; Pickett B; McLaughlin PW; Sandler HM; Roach M
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):36-42. PubMed ID: 19409729
[TBL] [Abstract][Full Text] [Related]
9. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
Kollmeier MA; Fidaleo A; Pei X; Cohen G; Zaider M; Mo Q; Cox B; Yamada Y; Zelefsky MJ
BJU Int; 2013 Jun; 111(8):1231-6. PubMed ID: 23551568
[TBL] [Abstract][Full Text] [Related]
10. High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes.
Falk AT; Demontoy S; Chamorey E; Chand ME; Gautier M; Azria D; Zaki S; Chevallier D; Cham Kee DL; Hannoun-Lévi JM
Brachytherapy; 2017; 16(5):993-999. PubMed ID: 28754301
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer.
Aström L; Pedersen D; Mercke C; Holmäng S; Johansson KA
Radiother Oncol; 2005 Feb; 74(2):157-61. PubMed ID: 15734203
[TBL] [Abstract][Full Text] [Related]
12. Updated results of high-dose rate brachytherapy and external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
Pellizzon AC; Salvajoli J; Novaes P; Maia M; Fogaroli R
Int Braz J Urol; 2008; 34(3):293-301. PubMed ID: 18601759
[TBL] [Abstract][Full Text] [Related]
13. Two-fraction high-dose-rate brachytherapy within a single day combined with external beam radiotherapy for prostate cancer: single institution experience and outcomes.
Liu J; Kaidu M; Sasamoto R; Ayukawa F; Yamana N; Sato H; Tanaka K; Kawaguchi G; Ohta A; Maruyama K; Abe E; Kasahara T; Nishiyama T; Tomita Y; Aoyama H
J Radiat Res; 2016 Jun; 57(3):280-7. PubMed ID: 26983988
[TBL] [Abstract][Full Text] [Related]
14. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
15. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332
[TBL] [Abstract][Full Text] [Related]
16. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience.
Aluwini S; van Rooij PH; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1480-5. PubMed ID: 22285661
[TBL] [Abstract][Full Text] [Related]
17. Two decades of high dose rate brachytherapy with external beam radiotherapy for prostate cancer.
Åström L; Grusell E; Sandin F; Turesson I; Holmberg L
Radiother Oncol; 2018 Apr; 127(1):81-87. PubMed ID: 29496280
[TBL] [Abstract][Full Text] [Related]
18. The 15-year outcomes of high-dose-rate brachytherapy for radical dose escalation in patients with prostate cancer - a benchmark for high-tech external beam radiotherapy alone?
Galalae RM; Zakikhany NH; Geiger F; Siebert FA; Bockelmann G; Schultze J; Kimmig B
Brachytherapy; 2014; 13(2):117-22. PubMed ID: 24360880
[TBL] [Abstract][Full Text] [Related]
19. The dosimetry of prostate brachytherapy-induced urethral strictures.
Merrick GS; Butler WM; Tollenaar BG; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):461-8. PubMed ID: 11872293
[TBL] [Abstract][Full Text] [Related]
20. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?
Morton G; Loblaw A; Cheung P; Szumacher E; Chahal M; Danjoux C; Chung HT; Deabreu A; Mamedov A; Zhang L; Sankreacha R; Vigneault E; Springer C
Radiother Oncol; 2011 Sep; 100(3):463-7. PubMed ID: 21924511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
